Search
for
Sort by
Research 30 of 1000+
- Assessment of biotin supplementation among patients in an outpatient dermatology clinic
- Synthetic hair implantations continue; serious complications result
- Synthetic hair implantations continue; serious complications result
- Biotin beware: Perils of biotin supplementation: Response to: “The epidemiology, impact, and diagnosis of micronutrient nutritional dermatoses. Part 2: B-complex vitamins”
- Global online interest in finasteride sexual side effects
- Global Online Interest in Finasteride Sexual Side Effects
- MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
- US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
- How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects
- Drug related lipid metabolism abnormalities: a real-world pharmacovigilance exploratory analysis based on U.S. FDA adverse event reporting system (FAERS)
- Fast-tracked innovation: orforglipron approval under the FDA’s National Priority Voucher program
- US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions
- Comment on “The post-finasteride syndrome: possible etiological mechanisms and symptoms”
- Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation
- CONSULTING “DR. GOOGLE” FOR FINASTERIDE SEXUAL SIDE EFFECTS: A CONTEMPORARY WORLDWIDE TRENDS ANALYSIS
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Response to: “Rethinking biotin therapy for hair, nail, and skin disorders”
- Finasteride in Androgenic Alopecia
- Apply directly to the forehead: Holmes, Nana, and hennapecia
- Rethinking biotin therapy for hair, nail, and skin disorders
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Unequal Protection Under the Law: Why FDA Should Use Negotiated Rulemaking to Reform the Regulation of Generic Drugs
- Hair Care Cosmetics Regulation in Different Countries – A Comparative Study
- New changes in pregnancy and lactation labelling: Review of dermatologic drugs
- A History of Drug Advertising: The Evolving Roles of Consumers and Consumer Protection
- Bidirectional Barbed Sutures for Wound Closure: Evolution and Applications
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system